MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

Data ReadoutpositiveMN-001Positive

AI Analysis

Summary

MediciNova announced positive topline results from the Phase 2 MN-001-NATG-202 trial showing MN-001 (Tipelukast) achieved statistically significant increases in HDL cholesterol and particle count, with early triglyceride reduction, body weight reduction, and improved liver fat metrics.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Statistically significant increases in HDL-C and HDL-P, significant early reduction in triglyceride, reduction in body weight, and numerical improvement in liver fat

Importance:6/10

Sentiment:

0.75

Phase 2 datametabolic diseaseHDLtriglyceridesliver fat

Related Companies

$MNOV

Read the original article

Published by GlobeNewswire Clinical Studies on September 28, 2026 10:00 AM

Read Original